Barclays PLC Purchases 6,905 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Barclays PLC lifted its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 357.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,837 shares of the medical instruments supplier’s stock after acquiring an additional 6,905 shares during the quarter. Barclays PLC owned 0.16% of Mesa Laboratories worth $1,148,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new position in shares of Mesa Laboratories during the second quarter valued at approximately $26,000. FMR LLC increased its position in Mesa Laboratories by 34.1% during the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 100 shares during the period. Quantbot Technologies LP purchased a new position in Mesa Laboratories during the third quarter valued at approximately $70,000. Sanctuary Advisors LLC purchased a new position in shares of Mesa Laboratories in the 2nd quarter valued at $183,000. Finally, Berry Wealth Group LP bought a new position in shares of Mesa Laboratories in the 3rd quarter worth $204,000. 90.60% of the stock is currently owned by institutional investors.

Insider Activity

In other Mesa Laboratories news, CEO Gary M. Owens sold 2,518 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the completion of the sale, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This trade represents a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.40% of the company’s stock.

Mesa Laboratories Stock Performance

Shares of MLAB stock opened at $133.06 on Monday. The company has a market capitalization of $722.65 million, a P/E ratio of -2.92 and a beta of 0.86. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $141.17. The business’s 50 day moving average is $120.56 and its two-hundred day moving average is $117.45. The company has a current ratio of 0.70, a quick ratio of 0.51 and a debt-to-equity ratio of 0.65.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 29th were paid a $0.16 dividend. The ex-dividend date of this dividend was Friday, November 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.48%. Mesa Laboratories’s dividend payout ratio is currently -1.40%.

Wall Street Analyst Weigh In

Several research firms have issued reports on MLAB. Evercore ISI lifted their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com cut shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.